2.34
+2.63%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About 4DMedical
Its shares trade on ASX under the ticker 4DX.AX. It has been listed since 7 August 2020. In the fiscal year to 30 June 2026, it reported revenue of A$7.1m and a net loss of A$204.4m. At that date it held total assets of A$365.3m and shareholders' equity of A$170.2m.
4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-08-07. Through its flagship patented XV Technology, the Company enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers its FDA-cleared XV Lung Ventilation Analysis Software (XV LVA), which is a modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS. XV LVAS and CT LVAS reports are prepared using the Company’s software as a service (SaaS) delivery model using existing hospital imaging equipment or the Company's XV Scanner. The company initiated the commercial rollout of XV LVAS with I-MED Radiology Network (I-MED), which is a diagnostic imaging provider with approximately 250 clinics nationwide. The firm provides its lung imaging technology to other selected clinics across the I-MED network.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 7 Aug 2020
- Website
- 4dmedical.com ↗
Leadership
Pay as last reported
- Ms. Lilian BianchiNon-Executive Chairman of the BoardA$22,667
- Dr. Andreas FourasChief Executive Officer, Managing Director, Executive DirectorA$1.3m
- Mr. Chris CoxInterim Chief Financial Officer
- Mr. Hamish GeorgeCompany Secretary
- Mr. John LivingstonNon-Executive Director, since 2018A$170,464
- Ms. Geraldine McgintyNon-Executive Director
- Dr. Robert FiglinNon-Executive Independent DirectorA$50,000
- Mr. Julian SuttonNon-Executive Independent DirectorA$382,017
- Mr. Simon HinsleyInvestor Relations, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- XV Technology enables physicians to understand regional airflow in the lungs with greater sensitivity.
- XV LVA and CT LVAS reports are prepared using SaaS delivery model with existing hospital imaging equipment.
- I-MED Radiology Network provides 250 clinics nationwide for commercial rollout of XV LVAS.
Weaknesses
- XV Technology is limited to lung imaging applications without broader medical imaging capabilities.
- XV LVAS and CT LVAS require existing hospital imaging equipment for operation.
- The company's commercial rollout is currently limited to I-MED Radiology Network clinics.
Opportunities
- Expanding XV Technology to other medical imaging applications beyond lung imaging.
- Increasing adoption of XV LVA and CT LVAS in additional clinics across I-MED network.
- Developing partnerships with other diagnostic imaging providers for wider commercialization.
Threats
- Competition from other medical imaging technology companies in the Health Care sector.
- Regulatory changes affecting FDA-cleared medical software in the United States.
- Dependence on I-MED Radiology Network for initial commercial rollout.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.